Skip to main content
Karo Pharma AB logo

Karo Pharma AB — Investor Relations & Filings

Ticker · KARO ISIN · SE0007464888 LEI · 213800G54Z51LOPGTA79 ST Manufacturing
Open in API
Filings indexed 653 across all filing types
Latest filing 2022-02-25 Interim / Quarterly Rep…
Country SE Sweden
Listing ST KARO

About Karo Pharma AB

https://www.karohealthcare.com/

Karo Pharma AB, operating as Karo Healthcare, is a healthcare company that develops, markets, and sells a broad portfolio of everyday healthcare products. The company's offerings are designed to prevent illness and treat common health problems, empowering consumers to manage their daily well-being. The portfolio consists of various branded medicines and consumer healthcare products distributed through pharmacies and directly to healthcare providers. With products available in over 90 countries, the company focuses on becoming a leading force in its sector by employing a consumer-centric approach, strategic innovation, and omnichannel excellence.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2021
Interim / Quarterly Report Classification · 100% confidence The document is a 'Bokslutskommuniké' (Year-end report) for Karo Pharma for the period ending December 2021. It contains comprehensive financial statements, including income statements, balance sheets, cash flow statements, and management commentary on financial performance. It is not a mere announcement (RPA) as it contains substantive financial data and analysis. It fits the definition of an Interim/Quarterly Report (IR) as it covers a specific fiscal period (Q4 and full year 2021) and provides detailed financial results. FY 2021
2022-02-25 Swedish
Audit Report / Information 2021
Audit Report / Information Classification · 98% confidence The document is explicitly titled "Karo Pharma Year-end report" and contains a detailed Table of Contents covering Q4 and the full year results (January - December 2021), including key financials, CEO comments, and consolidated statements (income statement, balance sheet, cash flow). This structure and content strongly indicate a comprehensive annual financial report. Although it mentions the 'Auditor's review' section, it states the report 'has not been subject to auditor's review,' which is common for preliminary year-end reports or specific regulatory filings that precede the final audited 10-K filing, but the core content is the full annual performance review. Given the comprehensive nature covering the entire fiscal year and the title 'Year-end report', it aligns best with the Annual Report category (10-K), even if it might be a local equivalent or preliminary version, as it contains the full annual performance data, unlike a brief Earnings Release (ER) or a mere announcement (RPA). The length (47,515 chars) also supports it being a full report rather than an announcement. FY 2021
2022-02-25 English
Karo Pharma slutför förvärvet av Sylphar International NV
M&A Activity Classification · 99% confidence The document announces the completion of an acquisition ('Karo Pharma slutför förvärvet av Sylphar International NV') for 290 mEUR. It also mentions changes in management structure (Robin List joining the group management) and is issued under EU Market Abuse Regulation, suggesting it is a significant corporate event disclosure. This type of announcement, detailing a major transaction (M&A) and related management integration, fits best under the Merger/Takeover Activity (TAR) category, as the core event is the completion of an acquisition. It is not a standard earnings release (ER), quarterly report (IR), or a general regulatory filing (RNS), as the subject matter is highly specific to a transaction.
2022-01-13 Swedish
Karo Pharma completes the acquisition of Sylphar International NV
M&A Activity Classification · 99% confidence The document announces the successful completion of an acquisition (Karo Pharma acquiring Sylphar International NV) for a specific price (EUR 290m). It also mentions changes in management structure (Sylphar CEO joining the Karo Corporate Management Team). This type of corporate action, involving a significant transaction like an acquisition, is best classified under M&A Activity (TAR). While it touches on management changes (MANG), the primary focus and trigger for the announcement is the completion of the takeover/merger transaction. It is not a standard periodic report (10-K, IR, ER) or a general regulatory filing (RNS).
2022-01-13 English
Karo Pharma enters into an agreement for the potential acquisition of the E45® brand from Reckitt
M&A Activity Classification · 99% confidence The document text describes a specific corporate action: Karo Pharma entering into an agreement for the potential acquisition of the E45® brand from Reckitt. This involves a significant transaction, financing details (100% debt financed), and expected closing timelines. This type of announcement, detailing a merger or takeover proposal, directly aligns with the definition of M&A Activity (TAR). It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), as it focuses on a strategic transaction rather than periodic financial performance reporting. It is a specific corporate event announcement, making TAR the most appropriate classification over the general Regulatory Filing (RNS). The document length (4510 chars) is substantial enough to be the primary announcement, not just a brief notice of publication (RPA).
2021-12-24 English
Karo Pharma ingår avtal med avsikt att förvärva E45® från Reckitt
M&A Activity Classification · 99% confidence The document is a press release from Karo Pharma AB announcing an agreement to potentially acquire the E45® brand from Reckitt for 200 million GBP. It details the terms, expected closing date (Q2 2022), strategic rationale, and financing method (100% debt). Crucially, the final paragraph states: "Denna information är sådan som Karo är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such that Karo is obliged to disclose pursuant to the EU Market Abuse Regulation) and provides a specific release time (December 24, 2021). This structure—a formal announcement of a significant corporate event mandated by market regulations, presented as a brief press release—is characteristic of a general regulatory filing or market disclosure that doesn't fit the specific financial report categories (10-K, IR, ER). Since it is a mandatory disclosure under MAR but not a specific report type like a dividend notice (DIV) or management dealing (DIRS), the most appropriate classification is the general regulatory announcement category, RNS (Regulatory Filings). The document length (4530 chars) is short, supporting the idea that it is an announcement rather than the full report itself.
2021-12-24 Swedish

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.